Biocon is commercially launching two biosimilars, Aukelso and Bosaya (both denosumab-kyqq) in the United States. Aukelso is a biosimilar to Xgeva, and Bosaya is a biosimilar to Prolia, both Amgen products. Aukelso and Bosaya Background The U.S. FDA granted interchangeable designations to both Aukelso and Bosaya in September 2025, permitting substitution at the pharmacy level. Aukelso and Bosaya are now available by prescription through specialty pharmacies—in accordance with state laws—and...